ABBV
NYSE · Biotechnology
Abbvie Inc
$246.04
+2.17 (+0.89%)
Financial Highlights (FY 2026)
Revenue
60.42B
Net Income
4.17B
Gross Margin
71.6%
Profit Margin
6.9%
Rev Growth
+1.8%
D/E Ratio
20.19
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 71.6% | 71.6% | 41.9% | 41.9% |
| Operating Margin | 24.6% | 22.2% | 4.7% | 4.9% |
| Profit Margin | 6.9% | 6.6% | 3.7% | 3.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 60.42B | 59.38B | 206.54B | 154.58B |
| Gross Profit | 43.27B | 42.53B | 86.47B | 64.71B |
| Operating Income | 14.89B | 13.17B | 9.72B | 7.57B |
| Net Income | 4.17B | 3.69B | 7.53B | 5.59B |
| Gross Margin | 71.6% | 71.6% | 41.9% | 41.9% |
| Operating Margin | 24.6% | 22.2% | 4.7% | 4.9% |
| Profit Margin | 6.9% | 6.6% | 3.7% | 3.6% |
| Rev Growth | +1.8% | +1.8% | +21.3% | +19.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 205.31B | 205.31B | 60.07B | 57.45B |
| Total Equity | 10.17B | 10.17B | 267.56B | 258.44B |
| D/E Ratio | 20.19 | 20.19 | 0.22 | 0.22 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 15.65B | 14.61B | 15.67B | 11.30B |
| Free Cash Flow | — | — | 10.35B | 8.18B |